reports
Alvotech Reports Financial Results for First Quarter of 2024 and Provi...
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year. Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year. Alvotech signed new commercialization agreements for its high concentration interchangeable biosimilar to Humira® in the U.S. and for its proposed biosimilar to Prolia® and Xgeva® in the U.S. and Europe. Alvotech raises topline revenue guidance to $400-$500 million and tightens guidance for b...
Alvotech Reports Financial Results for First Quarter of 2024 and Provi...
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last yearGross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year. Alvotech signed new commercialization agreements for its high concentration interchangeable biosimilar to Humira® in the U.S. and for its proposed biosimilar to Prolia® and Xgeva® in the U.S. and Europe. Alvotech raises topline revenue guidance to $400-$500 million and tightens guidance for bottom...
Alvotech and Dr. Reddy’s enter into collaboration for commercializatio...
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)Alvotech will be responsible for development and manufacture of the product HYDERABAD, INDIA & REYKJAVIK, ICELAND — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Red...
Alvotech gengur til samstarfs við Dr. Reddy‘s um markaðssetningu AVT03...
Alvotech gengur til samstarfs við Dr. Reddy‘s um markaðssetningu AVT03, fyrirhugaðrar hliðstæðu við Prolia og Xgeva, í Bandaríkjunum og Evrópu Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði gert samstarfssamning við Dr. Reddy’s Laboratories SA, dótturfyrirtæki Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) um sölu- og markaðssetningu AVT03, fyrirhugaðrar líftæknilyfjahliðstæðu Alvotech við Prolia og Xgeva, sem bæði innnihalda denosumab. Dr. Reddy er alþjóðlegt lyfjafyrirtæki með höfuðstöðvar á Indlandi en starfsemi um allan heim. Prolia og Xgeva eru líftæknilyf við ýmsum þr...
Alvotech and Dr. Reddy’s enter into collaboration for commercializatio...
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and manufacture of the product HYDERABAD, India and REYKJAVIK, Iceland, May 21, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines fo...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now A...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, Iceland and PARSIPPANY, N.J., May 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthrit...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now A...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult an...
Alvotech og Teva Pharmaceuticals hefja sölu á líftæknilyfjahliðstæðunn...
Alvotech og Teva Pharmaceuticals hefja sölu á líftæknilyfjahliðstæðunni Simlandi í Bandaríkjunum Simlandi er fyrsta líftæknilyfjahliðstæðan í háum styrk með útskiptanleika við Humira á markaði í Bandaríkjunum Alvotech (NASDAQ: ALVO) og samstarfsaðili þess Teva Pharmaceuticals Ltd. tilkynntu í dag að sala væri hafin í Bandaríkjunum á Simlandi (adalimumab-ryvk), fyrstu líftæknilyfjahliðstæðunni í háum styrk með útskiptanleika við Humira sem hlotið hefur markaðsleyfi frá Matvæla- og lyfjaeftirliti Bandaríkjanna (FDA). „Við erum stolt af því að geta boðið meðferðaraðilum og sjúklingum í Banda...
A-Mark Precious Metals Inc: 2 directors
Two Directors at A-Mark Precious Metals Inc sold after exercising options/sold 61,967 shares at between 38.091USD and 38.343USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades...
Alvotech S.A. Annual General Meeting to be held June 7, 2024
Alvotech S.A. Annual General Meeting to be held June 7, 2024 The Annual General Meeting of Alvotech S.A. will be held on Friday June 7, 2024, at 09.00 a.m. CEST at the premises of Arendt & Medernach S.A. at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand Duchy of Luxembourg. Reference is made to the attached document with regard to the final agenda. Meeting materials and all further information about the Annual General Meeting is available on the Alvotech website: . CONTACTS Alvotech Investor RelationsBenedikt Stefansson, Senior Director Attachment ...
Aðalfundur Alvotech S.A. boðaður 7. júní 2024
Aðalfundur Alvotech S.A. boðaður 7. júní 2024 Aðalfundur Alvotech S.A. verður haldinn föstudaginn 7. júní 2024, kl. 09.00 CEST á skrifstofu Arendt & Medernach S.A að 41A Avenue John F. Kennedy, L-1855 Lúxemborg. Drög af dagskrá fundarins er að finna í meðfylgjandi viðhengi. Fundargögn og allar frekari upplýsingar varðandi aðalfundinn er hægt að nálgast á heimasíðu félagsins . Nánari upplýsingar veitir: Alvotech, fjárfestatengslBenedikt Stefánsson, forstöðumaður Viðhengi
- Wedbush Research
BLUE BLUEBIRD BIO INC.
TPH TRI POINTE HOMES INC.
TOL TOLL BROTHERS INC.
MTH MERITAGE HOMES CORPORATION
LGIH LGI HOMES INC.
LEN LENNAR CORPORATION CLASS A
KBH KB HOME
JACK JACK IN THE BOX INC.
FATE FATE THERAPEUTICS INC
CCS CENTURY COMMUNITIES INC.
BPMC BLUEPRINT MEDICINES CORP.
AZO AUTOZONE INC.
DHI D.R. HORTON INC.
TMHC TAYLOR MORRISON HOME CORPORATION
ORLY O'REILLY AUTOMOTIVE INC.
ACET ADICET BIO INC
BEAM BEAM THERAPEUTICS
COGT COGENT BIOSCIENCES INC
DFH DREAM FINDERS HOMES
NUVB NUVATION BIO INC (A)
TSVT 2SEVENTY BIO INC
GMTX GEMINI THERAPEUTICS INC
PEPG PEPGEN INC
SDHC SMITH DOUGLAS HOMES CORP
- Brian Violino
- Jay McCanless
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and ...
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today reported financial results for the first quarter en...
Rani Therapeutics to Participate in May Investor Conferences
Rani Therapeutics to Participate in May Investor Conferences SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in May 2024. These conferences include: H.C. Wainwright 2nd Annual BioConnect Investor ConferenceLocation: The Nasdaq Headquarters, New York CityDate: Monday, May 20th at 2:30pm E.TFormat: Fireside Chat and 1x1 Investor ...
Alvotech Announces Webcast of First Quarter 2024 Financial Results on...
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2024, after U.S. markets close on Tuesday, May 21, 2024. Alvotech will also conduct a conference call with analysts to present the first quarter 2024 financial results and recent business highlights on Wednesday May 22, 2024, at 8:00 am EDT (12...
Alvotech kynnir uppgjör fyrsta ársfjórðungs 2024 22. maí nk. kl. 12 a...
Alvotech kynnir uppgjör fyrsta ársfjórðungs 2024 22. maí nk. kl. 12 að íslenskum tíma Alvotech (NASDAQ: ALVO) mun senda út tilkynningu með uppgjöri fyrsta ársfjórðungs 2024 eftir lokun markaða í Bandaríkjunum, þriðjudaginn 21. maí nk. Þá mun Alvotech halda kynningarfund fyrir fjárfesta í beinu streymi miðvikudaginn 22. maí nk. kl. 12:00 á hádegi að íslenskum tíma. Streymi af kynningarfundinum, sem fer fram á ensku, verður aðgengilegt á fjárfestasíðu Alvotech, , á slóðinni . Þar verður einnig hægt að finna upptöku af fundinum eftir að honum er lokið, sem aðgengileg verður í 90 daga. U...
Alvotech Announces Webcast of First Quarter 2024 Financial Results on ...
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) REYKJAVIK, Iceland, May 13, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2024, after U.S. markets close on Tuesday, May 21, 2024. Alvotech will also conduct a conference call with analysts to present the first quarter 2024 financial results and recent busines...
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Del...
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024 SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company’s oral delivery platform, at Digestive Disease Week® (DDW) taking place both virtually and in-pers...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.